R. Halpenny

发表

Four-Year Follow-Up of Polyalkylimide Gel Use for the Treatment of HIV-Associated Lipoatrophy

C. Kovacs, T. Antoniou, M. Loutfy, 2011, HIV clinical trials.

Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy

C. Kovacs, T. Antoniou, M. Loutfy, 2009, AIDS care.

Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients

C. Kovacs, T. Antoniou, M. Loutfy, 2007, AIDS.

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection

R. Kaul, A. Jha, D. Nixon, 2008, The Journal of experimental medicine.

HIV-Specific CD8+ Lymphocytes in Semen Are Not Associated with Reduced HIV Shedding12

R. Kaul, M. Ostrowski, C. Kovacs, 2005, The Journal of Immunology.

HIV-Specific T-Cells Accumulate in the Liver in HCV/HIV Co-Infection

R. Kaul, M. Ostrowski, C. Kovacs, 2008, PloS one.

HPV genotyping and risk factors for anal high-risk HPV infection in men who have sex with men from Toronto, Canada

R. Kaul, M. Loutfy, S. Huibner, 2021, Scientific Reports.

Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy

R. Kaul, M. Ostrowski, C. Kovacs, 2011, AIDS.

Immune reconstitution in the sigmoid colon after long-term HIV therapy

R. Kaul, M. Ostrowski, C. Kovacs, 2008, Mucosal Immunology.

Distinct Transcriptional Profiles in Ex Vivo CD4+ and CD8+ T Cells Are Established Early in Human Immunodeficiency Virus Type 1 Infection and Are Characterized by a Chronic Interferon Response as Well as Extensive Transcriptional Changes in CD8+ T Cells

M. Ostrowski, C. Kovacs, L. Heisler, 2007, Journal of Virology.

Established Early in Human Immunodeficiency Virus Type 1 Infection and Are Characterized by a Chronic Interferon Response as Well as Extensive Transcriptional Changes in CD8 ! T Cells ! †

M. Ostrowski, C. Kovacs, L. Heisler, 2007 .

Why can't the immune system control HIV-1? defining HIV-1-specific CD4+ T cell immunity in order to develop strategies to enhance viral immunity

M. Ostrowski, C. Kovacs, M. Loutfy, 2006, Immunologic research.

HIV-Specific CD 8 Lymphocytes in Semen Are Not Associated with Reduced HIV Shedding 1 , 2

R. Kaul, M. Ostrowski, C. Kovacs, 2005 .

Prevalence of Sexually Transmitted Viral and Bacterial Infections in HIV-Positive and HIV-Negative Men Who Have Sex with Men in Toronto

R. Kaul, M. Loutfy, S. Huibner, 2016, PloS one.

"Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination.

W. Cunningham, M. Loutfy, A. Daley, 2011, Vaccine.

Adopting real-time surveillance dashboards as a component of an enterprisewide medication safety strategy.

Allison B McCoy, Lemuel R Waitman, John M. Starmer, 2011, Joint Commission journal on quality and patient safety.

Pharmacokinetics of Raltegravir in the Semen of HIV-Infectedmen

T. Antoniou, M. Loutfy, C. L. la Porte, 2014, Antiviral therapy.

Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men.

C. Kovacs, T. Antoniou, M. Loutfy, 2013, Journal of acquired immune deficiency syndromes.

Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial.

M. Loutfy, A. Daley, P. Newman, 2008, Vaccine.

Disproportionately high semen shedding of HIV is associated with compartmentalized cytomegalovirus reactivation.

Anthony Sheung, R. Kaul, C. Kovacs, 2006, The Journal of infectious diseases.

Virologic and Immunologic Impact and Durability of Enfuvirtide-Based Antiretroviral Therapy in HIV-Infected Treatment-Experienced Patients in a Clinical Setting

C. Kovacs, T. Antoniou, M. Loutfy, 2007, HIV clinical trials.